Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL)
Status:
Active, not recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
In this study, investigators are trying to see if infusion of T cells (called CTLs) will
prevent or treat cytomegalovirus (CMV), Epstein Barr Virus (EBV) and adenovirus (AdV)
reactivation or infection.
Patients with blood cell cancer, other blood disease or a genetic disease may receive a stem
cell transplant. After receiving transplant, they are at risk of infections until a new
immune system to fight infections grows from the cord blood cells. In this study,
investigators are trying to give special cells called T cells. These cells will try to fight
viruses that can cause infection.
Investigators will test to see if blood cells from donor that have been grown in a special
way, can prevent patients from getting an infection. EBV, AdV and CMV are viruses that can
cause serious life-threatening infections in patients who have weak immune systems after
transplant.
T lymphocytes can kill viral cells but normally there are not enough of them to kill all the
virus infected cells after transplant. Some researcher have taken T cells from a person's
blood, grown more of them in the laboratory and then given them back to the person during a
viral infection after a bone marrow transplant. Some of these studies have shown a positive
therapeutic effect in patients receiving the CTLs after a viral infection in the
post-transplant period.
Investigators will grow these cells from donor in the laboratory in a way that will train
them to recognize and remove viruses when the T cells are given after a transplant. Since
most donors have previously been infected with EBV, CMV, and adenovirus, investigators are
able to use their T cells that remember these viruses to grow the CTLs. However, they now
also have a new way of growing CTLs from donors who have not been infected with CMV.